Autoimmune encephalitis
Conditions
Interventions
Autoimmune encephalitis (AE) with psychiatric symptoms:None
AE without psychiatric symptoms:None
Patients with adolescent-onset schizophrenia:None
Sponsors
Peking University Sixth Hospital ( Institute of Mental Health )
Eligibility
Sex/Gender
All
Age
12 Years to 19 Years
Inclusion criteria
Inclusion criteria: 1. Age 12-19 years old, meet the criteria for the diagnosis of AE in the 2022 Chinese Expert Consensus on the Diagnosis and Treatment of Autoimmune Encephalitis (2022 Edition), and the blood and cerebrospinal fluid samples were tested by the Neurology Laboratory of Peking Union Medical College Hospital: A. Subacute (rapidly progressing within 3 months) onset of working memory deficits (short-term memory loss. , seizures, psychiatric symptoms, suggestive of limbic involvement. B. FLAIR sequence from MRI showing abnormal signal shadows on the medial temporal lobes of both sides. C. At least 1 of the following: a. Cerebrospinal fluid leukocytosis (white blood cell count > 5×10^6/L); b. EEG suggests epileptiform discharges or slow-wave activity originating from the temporal lobe. D. Reasonable exclusion of other causes. 2. All patients received first- or second-line immunotherapy. First-line immunotherapy includes glucocorticoids, gamma globulin, and plasma exchange, and second-line immunotherapy includes rituximab, mycophenol mofetil, azathioprine, etc. 3. Patients with ovarian teratoma will be treated with tumor resection. 4. Laboratory examination of cerebrospinal fluid AE-related antibody positive, antibody detection method is indirect immunofluorescence. All patients were tested for cerebrospinal fluid AE-related antibodies. 5. The patients were all autoimmune encephalitis, and the onset of the disease was not treated with hormonal immunotherapy. 6. Agree to cooperate with follow-up observation, improve the compliance of examination and treatment, and the clinical data are more complete.
Exclusion criteria
Exclusion criteria: 1. Exclude positive anti-neuronal antibodies caused by other diseases, such as herpes simplex virus and varicella-zoster virus infection; 2. Patients with a family history of other neurological diseases or psychiatric diseases, including viral encephalitis, glioma, neurosyphilis, metabolic encephalopathy, drug poisoning, rheumatic diseases, neurovascular diseases involving cerebrovascular diseases, mitochondrial diseases, etc.; 3. Patients with severe multi-system diseases: such as liver or kidney insufficiency, severe acid-base imbalance, gastrointestinal bleeding, fatal arrhythmia, severe brain injury, etc. 4. Those who are lost to follow-up or whose family members refuse to follow-up. 5. Patients with incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NEOS;MRS; | — |
Countries
China
Contacts
Public ContactYuan Junliang
Peking University Sixth Hospital ( Institute of Mental Health )
Outcome results
None listed